3-(羟基甲基)-[1,1-联苯]-4-羧酸 | 773872-85-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3-(羟基甲基)-[1,1-联苯]-4-羧酸
• 英文名称: 3'-(Hydroxymethyl)-[1,1'-biphenyl]-4-carboxylic acid
• 英文别名: 4-[3-(hydroxymethyl)phenyl]benzoic acid
• CAS: 773872-85-8
• 化学式: C₁₄H₁₂O₃
• 分子量: 228.247
• InChiKey: HPXYVZSLBXTFMD-UHFFFAOYSA-N

物化性质

• 沸点：
  443.4±33.0 °C(Predicted)
• 密度：
  1.260±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  57.5
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 海关编码：
  2918199090

反应信息

• 作为反应物：
  描述：

  3-(羟基甲基)-[1,1-联苯]-4-羧酸 在 氯化亚砜 作用下， 以 四氢呋喃 、 N,N-二甲基甲酰胺 为溶剂， 反应 15.0h， 生成
  参考文献：
  名称：

  Design, synthesis, and SAR of anthranilamide-based factor Xa inhibitors incorporating substituted biphenyl P4 motifs

  摘要：

  Anthranilamides 4 and 5 were designed and synthesized as selective and orally bioavailable factor Xa inhibitors. Structural modifications aimed at lowering their lipophilicity were performed at the central phenyl ring and at the S4 binding biphenyl region by incorporating water solublizing substituents. The resulting compounds (e.g., 7, 8, 14, 30a, and 32b) are highly potent in vitro, and show improved activity in human plasma-based thrombin generation assay. (C) 2004 Published by Elsevier Ltd.

  DOI：

  10.1016/j.bmcl.2003.11.079
• 作为产物：
  描述：

  3-溴苯甲醇 、 4-甲氧羰基苯硼酸 在 caesium carbonate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 生成 3-(羟基甲基)-[1,1-联苯]-4-羧酸
  参考文献：
  名称：

  Discovery of a potent and selective Bcl-2 inhibitor using SAR by NMR

  摘要：

  The Bcl-2 family of proteins plays a major role in the regulation of apoptosis, or programmed cell death. Overexpression of the anti-apoptotic members of this family (Bcl-2, Bcl-xL, and Mcl-1) can render cancer cells resistant to chemotherapeutic agents and therefore these proteins are important targets for the development of new anti-cancer agents. Here we describe the discovery of a potent, highly selective, Bcl-2 inhibitor using SAR by NMR and structure-based drug design which could serve as a starting point for the development of a Bcl-2 selective anti-cancer agent. Such an agent would potentially overcome the Bcl-xL mediated thrombocytopenia observed with ABT-263. (C) 2010 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2010.09.033

文献信息

• ARYL/HETARYLAMIDES AS MODULATORS OF THE EP2 RECEPTOR
  申请人：Buchmann Bernd

  公开号：US20090023741A1

  公开（公告）日：2009-01-22

  The present invention relates to aryl/hetarylamide derivatives of the general formula I, process for their preparation, and the use thereof for the manufacture of pharmaceutical compositions for the treatment of disorders and indications connected with the EP 2 receptor.

  本发明涉及通式I的芳基/杂环酰胺衍生物，其制备方法，以及用于制造治疗与EP2受体相关的疾病和适应症的药物组合物的用途。
• ARYL CARBOXAMIDE DERIVATIVES AS TTX-S BLOCKERS
  申请人：Yamagishi Tatsuya

  公开号：US20120232052A1

  公开（公告）日：2012-09-13

  The present invention relates to aryl carboxamide derivatives of formula (I), wherein Ar 1 is phenyl; Ar 2 is aryl; n is 1-4; X is —O—, —S—, —SO— or —SO 2 —, a prodrug thereof or a pharmaceutically acceptable salt thereof, which have blocking activities of voltage gated sodium channels as the TTX-S channels, and which are useful in the treatment or prevention of such disorders and diseases as pain in which voltage gated sodium channels are involved. The invention also relates to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases as pain in which voltage gated sodium channels are involved.

  本发明涉及公式（I）的芳基羧酰胺衍生物，其中Ar1是苯基；Ar2是芳基；n为1-4；X为—O—、—S—、—SO—或—SO2—，其前体药物或其药学上可接受的盐，具有阻断电压门控钠通道如TTX-S通道的活性，并在治疗或预防涉及电压门控钠通道的疾病和疾病，如疼痛方面中有用。本发明还涉及包含这些化合物的制药组合物以及这些化合物和组合物在预防或治疗涉及电压门控钠通道的疾病和疾病，如疼痛方面的使用。
• NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF
  申请人：TOYAMA CHEMICAL CO., LTD.

  公开号：EP1820795A1

  公开（公告）日：2007-08-22

  An anthranilic acid derivative represented by the general formula (X) [wherein R1 represents hydrogen or a carboxy-protecting group; R2 represents optionally substituted phenyl, a heterocyclic group, etc.; R3 represents optionally substituted phenyl, a monocyclic heterocyclic group, etc.; X1 represents carbonyl, etc.; X2 represents optionally substituted alkylene group, a bond, etc.; X3 represents oxygen, a bond, etc.; and X4 represents a group represented by the general formula -X5-X6- or -X6-X5- (wherein X5 means oxygen, a bond, etc.; and X6 means optionally substituted alkylene, a bond, etc.)] or a salt of the derivative. The derivative or salt has the inhibitory activity of MMP-13 production and is hence useful as a therapeutic agent for articular rheumatism, osteoarthritis, cancer, etc.

  通式(X)代表的蒽酸衍生物[其中 R1 代表氢或羧基保护基团；R2 代表任选取代的苯基、杂环基团等；R3 代表任选取代的苯基、单环杂环基团等；X1 代表羰基等；X2 代表任选取代的亚烷基、键等；X3 代表氧、键等；X4 代表通式 -X5-X6- 或 -X6- 所代表的基团。X2 代表任选取代的亚烷基、键等；X3 代表氧、键等；X4 代表通式 -X5-X6- 或 -X6-X5- 所代表的基团（其中 X5 代表氧、键等；X6 代表任选取代的亚烷基、键等）]或衍生物的盐。衍生物或盐具有抑制 MMP-13 生成的活性，因此可用作关节风湿病、骨关节炎、癌症等的治疗剂。
• Piperazine derivatives as MAGL inhibitors
  申请人：Hoffmann-La Roche Inc.

  公开号：US11390610B2

  公开（公告）日：2022-07-19

  The invention provides new heterocyclic compounds having the general Formula (I), or a pharmaceutically acceptable salt thereof, wherein R1, R2, X, Y1 and Y2 are as described herein, compositions including the compounds, processes of manufacturing the compounds and methods of using the compounds.

  本发明提供了具有通式（I）的新杂环化合物或其药学上可接受的盐、 其中 R1、R2、X、Y1 和 Y2 如本文所述。
• PIPERAZINE DERIVATIVES AS MAGL INHIBITORS
  申请人：F. Hoffmann-La Roche AG

  公开号：EP3694840B1

  公开（公告）日：2021-08-04